Fineline Cube

Follow:
14446 Articles
FDA Approves Imdelltra Label Update – Monitoring Time for First Two Doses Cut to 6–8 Hours from 22–24, Easing Delivery of Amgen's First‑in‑Class SCLC Immunotherapy
CompanyDrug

FDA Approves Imdelltra Label Update – Monitoring Time for First Two Doses Cut to 6–8 Hours from 22–24, Easing Delivery of Amgen’s First‑in‑Class SCLC Immunotherapy

FDA Accepts Takeda's NDA for Zasocitinib with Priority Review – Next‑Generation Oral TYK2 Inhibitor Nears Decision in Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

FDA Accepts Takeda’s NDA for Zasocitinib with Priority Review – Next‑Generation Oral TYK2 Inhibitor Nears Decision in Moderate‑to‑Severe Plaque Psoriasis

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

Bio‑heart Partners with Shenqi Medical to Commercialize BioHeart Bioabsorbable Stent – Advancing "Interventional Treatment Without Implantation" in China's Coronary Market
CompanyDeals

Bio‑heart Partners with Shenqi Medical to Commercialize BioHeart Bioabsorbable Stent – Advancing “Interventional Treatment Without Implantation” in China’s Coronary Market

Cheplapharm and Sanofi Move to Forge Strategic Partnership – Lovenox/Clexane Anchors 20‑Medicine Portfolio and Three‑Site Transfer in Exchange for 26.4 % Equity Stake
CompanyDeals

Cheplapharm and Sanofi Move to Forge Strategic Partnership – Lovenox/Clexane Anchors 20‑Medicine Portfolio and Three‑Site Transfer in Exchange for 26.4 % Equity Stake

Hengrui's SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement
CompanyDrug

Hengrui’s SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement

China Medical System Wins NMPA Clinical Trial Approval for CMS‑D001 – Highly Selective Oral TYK2 Inhibitor Targeting Systemic Lupus Erythematosus
CompanyDrug

China Medical System Wins NMPA Clinical Trial Approval for CMS‑D001 – Highly Selective Oral TYK2 Inhibitor Targeting Systemic Lupus Erythematosus

Ascentage Pharma Forges Strategic Research Collaboration with Peking University – Building a Collaborative Innovation System in Hematologic Oncology
CompanyDeals

Ascentage Pharma Forges Strategic Research Collaboration with Peking University – Building a Collaborative Innovation System in Hematologic Oncology

Eisai and Sinopharm Forge Promotional Partnership for Methycobal Injection – Full‑Lifecycle Collaboration to Broaden Access to Vitamin B12 Therapy in China
CompanyDeals

Eisai and Sinopharm Forge Promotional Partnership for Methycobal Injection – Full‑Lifecycle Collaboration to Broaden Access to Vitamin B12 Therapy in China

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Company

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen
CompanyDrug

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market
CompanyDrug

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market